A new plain language summary of publication from Future Rare Diseases discusses the results of the LINC 4 study, which looked at how effective osilodrostat was in patients with Cushing’s disease and what the side effects were.
Read the summary here.
The original article on which this summary is based is called ‘Randomized Trial of Osilodrostat for the Treatment of Cushing Disease’ and was originally published in The Journal of Clinical Endocrinology & Metabolism. The original article can be read here.